Medrol (Methylprednisolone) Tablets

Medrol is the established brand name for methylprednisolone, an intermediate-acting oral corticosteroid that doctors prescribe to dampen down inflammation and an overactive immune response. We offer Medrol as tablets for oral use in four strengths: 4 mg, 8 mg, 16 mg and 32 mg, each available in a range of pack sizes. It belongs to the same broad corticosteroid family as prednisolone and dexamethasone, but methylprednisolone has its own particular potency, duration of action and side-effect profile that shape how and when it tends to be chosen. This article explains what the tablets contain, how methylprednisolone works, what general dosing and safety look like, and how it compares with related steroid medicines, including prednisolone, which we also stock.

Understanding Inflammation and Why Steroids Are Used

Many chronic and acute conditions, from asthma flares and severe allergic inflammation to ulcerative colitis and rheumatoid arthritis, share an underlying feature: the immune system produces too much inflammatory activity, causing swelling, pain, tissue damage or an allergic cascade. Corticosteroids such as methylprednisolone mimic the body's own stress hormone, cortisol, but at doses strong enough to suppress this excess inflammatory signalling. Because the same mechanism applies across very different organ systems, methylprednisolone tablets are used for skin flare-ups, joint disease, bowel inflammation and allergic disorders alike, even though these conditions look unrelated on the surface.

How Methylprednisolone Works

Methylprednisolone binds to glucocorticoid receptors inside cells throughout the body. Once bound, the receptor complex moves into the cell nucleus and alters the expression of genes that control inflammation, reducing the production of prostaglandins, cytokines and other chemical messengers that drive swelling, redness and immune cell activity. This also suppresses the migration of white blood cells to sites of irritation, which is why corticosteroids can calm flare-ups relatively quickly. Anti-inflammatory effects typically begin within a few hours of an oral dose, though the fullest benefit in chronic conditions such as ulcerative colitis or arthritis often builds over several days of continued treatment.

What the Evidence Shows

Methylprednisolone has decades of clinical use for conditions that respond to systemic corticosteroid treatment. Studies and clinical experience support the ability of systemic corticosteroids to control acute inflammatory and autoimmune flares, including selected exacerbations of asthma and chronic obstructive pulmonary disease, active ulcerative colitis, severe allergic inflammation and various forms of arthritis. The medicine treats inflammation rather than removing every underlying cause, so symptoms may return if the triggering disease remains active. Corticosteroids are generally used at the lowest effective dose for the shortest suitable period because their benefits must be weighed against cumulative adverse effects. For chronic autoimmune disease, methylprednisolone is often used as bridge or add-on treatment while a disease-modifying medicine takes effect rather than as a permanent standalone solution.

Formulation and Ingredients

Each Medrol tablet contains methylprednisolone as the active ingredient, formulated for oral administration and swallowed with water. The tablets are manufactured in four strengths, 4 mg, 8 mg, 16 mg and 32 mg, allowing a prescriber to tailor the total daily dose fairly precisely, including tapering schedules that gradually reduce the amount taken as treatment comes to an end. As with any tablet formulation, inactive excipients such as binders and fillers are present alongside the active ingredient; anyone with a known lactose or excipient sensitivity should check the specific pack information before starting treatment.

Established Uses of Medrol

Oral methylprednisolone is used for a broad range of corticosteroid-responsive conditions, including allergic disorders, inflammatory skin conditions, ulcerative colitis and various forms of arthritis. In allergic disease, a clinician may prescribe a short course for selected severe or persistent inflammation that has not responded sufficiently to initial treatment; a corticosteroid does not replace adrenaline and emergency care for anaphylaxis. In dermatology, it may be used for widespread or severe inflammatory skin conditions that have not settled with topical treatment. In ulcerative colitis, methylprednisolone can help bring an active flare under control while longer-term maintenance treatment takes effect. In arthritis, particularly rheumatoid arthritis and related autoimmune joint conditions, it may reduce joint swelling and pain during flares or while slower-acting medicines reach full effect. Anyone exploring these treatment areas more broadly may also find our anti-inflammatory medicines useful for comparison.

Strengths, Packaging and General Dosing Principles

We offer 4 mg Medrol in packs of 60, 90, 120, 180, 270 or 360 tablets. The 8 mg strength is available in packs of 30, 60, 90, 120, 180, 270 or 360 tablets; the 16 mg strength in packs of 30, 60, 90, 120, 180 or 270 tablets; and the 32 mg strength in packs of 60, 120 or 240 tablets.

Oral methylprednisolone dosing is highly individualised. A prescriber selects the starting dose according to the condition, its severity and the patient's response, and may subsequently reduce it to the lowest dose that maintains control. When a once-daily regimen is prescribed, taking the dose in the morning can better follow the body's natural cortisol rhythm. Taking tablets with or just after food may reduce stomach irritation, but the directions supplied by the prescriber and product leaflet take priority.

Methylprednisolone must not be stopped suddenly after prolonged treatment or certain high-dose courses because the body's natural corticosteroid production may have become suppressed. A clinician should determine whether a gradual taper is needed; repeated short courses, evening dosing and other risk factors can also affect that decision. If a dose is forgotten, the patient should follow the pack leaflet or ask a pharmacist or prescriber rather than taking a double dose. The dose, frequency and tapering schedule should never be changed independently.

Elimination and Half-Life

Methylprednisolone has a plasma half-life of roughly two to three hours, but its biological effect on inflammation lasts considerably longer, typically between 18 and 36 hours. It is therefore classed as an intermediate-acting corticosteroid, with a longer biological action than hydrocortisone but a shorter one than dexamethasone. It is metabolised mainly in the liver and its metabolites are excreted largely through the kidneys. This intermediate duration permits once-daily dosing for some conditions and carefully selected alternate-day regimens for some patients, although the appropriate schedule depends on the disease and clinical response.

Important Safety Information

Methylprednisolone is often well tolerated during a short course, but because it affects many body systems, health factors should be reviewed with a prescriber or pharmacist before treatment. Important considerations include allergies, other medicines, current or previous infections, diabetes, high blood pressure, stomach ulcers, osteoporosis, eye disease, mental health conditions, pregnancy and breastfeeding.

Working through these points before the first dose helps identify anyone who may need closer monitoring, a different dose or an alternative treatment. Our pharmacist team is happy to discuss general medicine and ordering questions before you order, but individual diagnosis and dose selection remain matters for the treating clinician.

Monitoring depends on dose and treatment length. Longer courses may require checks of blood pressure, weight, blood glucose and electrolytes, as well as attention to bone health, eye health, infection risk and adrenal suppression. Children receiving prolonged systemic corticosteroid treatment require growth and development monitoring. People taking longer-term or high-dose treatment may be advised to carry a steroid treatment card and should tell healthcare professionals about their corticosteroid use before surgery, vaccination or emergency treatment.

Prescription Requirements and Ordering Through Us

In the United Kingdom, oral methylprednisolone is classified as a Prescription Only Medicine, meaning it is ordinarily supplied against a prescription issued by a doctor or another authorised prescriber. Ordering Medrol through us does not require you to submit a prescription before we accept your order, and our pharmacist-supported team is available 24/7 by email, live chat and phone if you have questions before or after ordering. Available official records do not confirm an active UK marketing authorisation for the exact Medrol tablet pack or any of its listed strengths, so we recommend confirming suitability with a prescriber, especially for longer courses or higher doses. We have been supplying medicines online since 2017 and pack every order discreetly for delivery across the UK.

Who Should Avoid Methylprednisolone

Methylprednisolone should not be used by anyone with a known hypersensitivity to methylprednisolone or any tablet excipient. Systemic corticosteroids are generally contraindicated in people with systemic infections unless appropriate anti-infective treatment is being given. Particular caution is required with active peptic ulcer disease, osteoporosis, uncontrolled diabetes, significant hypertension, severe psychiatric illness or a recent heart attack because corticosteroids can worsen these problems. Live vaccines are usually avoided while a person is receiving immunosuppressive corticosteroid doses. Anyone with a current or recent serious infection, or recent exposure to chickenpox, shingles or measles, should seek clinical advice promptly because methylprednisolone can mask signs of infection and reduce the body's ability to fight it.

Interactions With Other Medicines

Methylprednisolone is metabolised through the CYP3A4 liver enzyme pathway, so medicines that inhibit this enzyme, such as ketoconazole, clarithromycin and certain HIV medicines containing ritonavir or cobicistat, can raise methylprednisolone exposure and increase adverse effects. Enzyme inducers such as rifampicin, phenytoin and carbamazepine can reduce its effect. These combinations may require avoidance, dose adjustment or closer monitoring by a clinician.

Combining methylprednisolone with non-steroidal anti-inflammatory drugs can increase the risk of stomach irritation, ulceration and gastrointestinal bleeding. Its use alongside anticoagulants may alter anticoagulant control, requiring closer monitoring. Methylprednisolone can raise blood glucose and change requirements for insulin or oral diabetes medicines, while combination with potassium-depleting diuretics may increase the risk of low potassium. The response to vaccines may be reduced, and live vaccines may be unsafe at immunosuppressive doses. Anyone taking prescription or over-the-counter medicines, supplements or herbal remedies should mention them before starting methylprednisolone.

Side Effects and When to Seek Help

Short courses of methylprednisolone can cause increased appetite, indigestion, fluid retention, sleep disturbance and mood changes such as increased energy or irritability. Longer or higher-dose courses carry a greater risk of weight gain, raised blood pressure, elevated blood glucose, weakened bones, muscle weakness, easy bruising, slower wound healing, cataracts, glaucoma and a rounder facial appearance. The likelihood of these effects generally rises with dose, duration and repeated exposure, although individual responses vary.

Some effects require prompt medical attention rather than routine monitoring. These include severe stomach pain, black or tarry stools, vomiting blood, sudden vision changes, facial swelling or difficulty breathing, symptoms of a serious infection, or new confusion, depression, mania or other severe mood disturbance. Psychiatric effects can occasionally begin within days or weeks of starting treatment. A person who becomes profoundly tired, dizzy, faint, nauseated or hypotensive after reducing or stopping corticosteroid treatment should seek urgent medical advice because these symptoms may indicate adrenal insufficiency.

Suspected side effects can be reported through the MHRA's Yellow Card Scheme, which helps monitor medicine safety across the UK. Patients should also tell the clinician managing their treatment, particularly if symptoms are severe, persistent or unexpected.

Overdose and Accidental Ingestion

A single accidental extra dose of methylprednisolone is unlikely to cause serious harm in most adults, although it may temporarily worsen effects such as stomach upset, raised blood glucose, fluid retention, insomnia or restlessness. Repeated overuse or very high doses taken over time are more concerning and can produce pronounced Cushingoid features, substantial metabolic disturbance, infection risk or severe mood changes. Anyone who has taken substantially more than directed, or if a child has swallowed the tablets accidentally, should contact NHS 111 or another urgent medical service for advice. Emergency care is appropriate if serious symptoms develop. The packaging should be kept available so the exact strength and quantity can be identified.

Storage

Store Medrol tablets at 20°C to 25°C in a tightly closed container, away from excess heat and moisture, such as in a suitable cupboard rather than a bathroom cabinet. Keep the tablets in their original packaging so that the printed strength, batch and expiry information remain available, and keep all medicines out of the sight and reach of children. Unused or expired tablets should be returned to a pharmacy for safe disposal rather than placed in household waste or flushed away.

Benefits and Trade-offs: Methylprednisolone and Other Corticosteroids

Methylprednisolone sits in the middle of the corticosteroid spectrum in terms of duration of action and has slightly greater anti-inflammatory potency than prednisolone by weight. This makes it a versatile option for many inflammatory conditions without the very long biological action of dexamethasone or the shorter action of hydrocortisone.

In practice, methylprednisolone has less mineralocorticoid activity than prednisolone and may cause somewhat less sodium and fluid retention at an equivalent anti-inflammatory dose. This is one reason a prescriber may favour it when fluid retention is a particular concern, although blood pressure, glucose, bone and infection risks still require attention. Dexamethasone's longer action can suit conditions needing sustained suppression, while hydrocortisone's shorter action and mineralocorticoid activity have different roles, including corticosteroid replacement in adrenal insufficiency. None of these differences makes one option universally better. The right choice depends on the condition, required duration, route, previous response and individual risk factors.

Generic Methylprednisolone, Prednisolone and Similar Medicines

Methylprednisolone is also available as a generic tablet. We separately stock Prednisolone, a closely related oral corticosteroid with a similar intermediate duration of action. It can be a therapeutic alternative, but methylprednisolone and prednisolone are not equivalent milligram for milligram; a clinician must calculate the appropriate dose when changing from one corticosteroid to another.

Methylprednisolone also exists in injectable formulations, including Solu-Medrol and Depo-Medrol. These are different products from oral Medrol tablets: Solu-Medrol is a soluble formulation used for intravenous or intramuscular administration, while Depo-Medrol is a depot suspension used by injection in selected settings. They are not part of our current range. Other systemic corticosteroids include prednisone, available under brand names such as Deltasone, and dexamethasone, which has a longer biological action. Readers managing inflammatory joint disease may also find our arthritis treatments useful for reviewing related options. Choosing between these medicines is a clinical decision based on the condition, required potency and duration, previous response and relevant health risks.